Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12 Items
Title  Creator  Group name  Publishing year 
[Non-pharmalogical interventions and breast cancer: What benefit in addition to radiotherapy?] Lognos et al. EquipeJPP 2022-06
Intraoperative partial irradiation for highly selected patients with breast cancer: Results of the INTRAOBS prospective study Lemanski et al. EquipeCTCS 2020-04
Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer Fabbro et al. EquipeCTCS 2020-08-05
[Antibodies, tools of choice for fluorescence-guided surgery] Pèlegrin et al. EquipeAP Dec 2019
Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients Framery et al. EquipeAP 2019
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help? Alexandre et al. EquipePC 2019
Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study Boogerd et al. EquipeAP Mar 2018
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers Guiu et al. EquipeELC Jul 2018
Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent Hoogstins et al. EquipeAP Jul 26, 2018
SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery Gutowski et al. EquipeCG Jun 2017
Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers Viala et al. EquipeCTCS Oct 2017
Oncoplastic Resection of Breast Cancers Located in the Lower-Inner or Lower-Outer Quadrant with the Modified McKissock Mammaplasty Technique Colombo et al. EquipeCTCS Dec 2015
12 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés